09 June 2016
Presbyopia is an ocular condition associated with age related loss of near vision. The eye loses the ability to focus well on near objects due to the hardening of the natural lens. It affects billions of people worldwide with the onset occurring around age 45. The most common treatment for presbyopia is the use of reading glasses. Recently, surgical correction of presbyopia has been tested as part of a clinical study by implanting a small device into the cornea, the clear front part of the eye. The Raindrop Near Vision Inlay is an investigational device that is being evaluated to treat this condition so that dependence upon reading glasses may be reduced in order to see objects up close.
18 April 2016
Marinus Pharmaceuticals (NASDAQ:MRNS) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ganaxolone for the treatment of status epilepticus, according to the agency’s website. Status epilepticus is a dangerous condition in which epileptic seizures follow one another without recovery of consciousness between them.
16 March 2016
One test that could detect four of the most common sexually transmitted infections in 30 minutes and allow them to be rapidly treated, will be developed by St George’s, University of London and diagnostics company Atlas Genetics.
15 March 2016
The world’s largest nation, Russia remains an attractive market for most industries. Nevertheless, the country has struggled through a rough economic period, rocked by a drop in the value of the currency and turbulence in the oil market. Geopolitical pressures have raised challenges, including sanctions imposed on the country.
04 March 2016
Syndax ($SNDX) has joined a small group of biotechs that has managed to price an IPO in the face of gale force market headwinds. The biotech had to go well under its projected range, though, and settle for $12.
03 March 2016
Over the past year, Syndax Pharmaceuticals has altered its strategic course and hired new management to implement it. And it looks like that change was big enough to propel Waltham, MA-based Syndax through the IPO queue on its second attempt since late 2014—albeit not on the terms the company had hoped for.
24 February 2016
Looking to cash in on its eventful past year, Syndax is upping its bet on a turbulent market with an IPO that will seek to garner about $66 million. The last time Syndax made a try at an IPO, it set out for a $60 million windfall. But this time, it's looking to trade on the rep of its new, high-profile CEO--AstraZeneca vet Briggs Morrison--and a string of partnerships with a who's who in immuno-oncology by selling 4.4 million shares at $14 to $16 per share. At most, it could gain up to $70 million, though the odds against a top-of-the-range response are intimidating.
19 February 2016
The Atlas io system was created by the University of Bath's spin-off biotech company Atlas Genetics in 2005. It has now won approval from the EU to be sold. The development means that patients can be tested and treated for the disease within a single clinic visit.
08 February 2016
A small biotech that started life at the University of Bath has won approval from European regulators to sell a device that tests for the sexually transmitted disease chlamydia in just 30 minutes.
04 February 2016
A few months ago, I met with Murali Prahalad, CEO of Epic Sciences (San Diego). We discussed the company’s methods of processing blood samples to store, identify and examine circulating tumor cells (CTCs). Since then I’ve been following reports on Epic’s method and other, competing CTC platforms.
30 September 2022
30 September 2022
29 September 2022
29 September 2022